SPEEDX
26.7.2021 18:42:07 CEST | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC). The rapid development of Plex Prime® SARS-CoV-2 Genotyping* tests will support investigations and monitoring of the range of emerging and circulating SARS-CoV-2 VOC that have been linked to increased transmissibility, reduced vaccine efficacy, or other characteristics that may require specific public health actions.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005313/en/
“Utilising our unique universal substrate approach, our rapid-response development team can easily respond to the complex and evolving situations arising from the ongoing COVID-19 pandemic” said Elisa Mokany, SpeeDx Chief Technology Officer. “Our unique technology excels in mutation detection applications and can readily be applied to variants reported in the SARS-CoV-2 sequence databases.”
Plex Prime® SARS-CoV-2 Alpha/Beta/Gamma+* the first product in the portfolio, is a single well multiplex designed to detect mutations N501Y, S982A and E484K in the spike gene of SARS-CoV-2 found in B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) VOC. A second multiplex for mutations related to the Delta VOC will be released shortly, and other mutations are currently under assessment. Compatible with standard qPCR instrumentation, the tests can reduce the manual process of preparing positive samples for sequence analysis by identifying samples of interest, focusing downstream activities, and ultimately reducing turn-around and hands-on time for laboratories.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
*available as Research Use Only reagents not for use in diagnostic procedures
References
- SARS-CoV-2 Variant Classifications and Definitions. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Found at: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenNx360 Capital Partners Promotes Pratik Rajeevan to Partner17.6.2026 13:00:00 CEST | Press release
GenNx360 Capital Partners (“GenNx360”), a New York City-based private equity firm investing in U.S. lower middle market industrial services and business services companies, is thrilled to announce the promotion of Pratik Rajeevan to Partner. Pratik has significant transaction experience having invested in over ten platform companies and 30 add-on investments during his tenure at GenNx360. His experience includes investments in aerospace and defense, utility and environmental services, and testing and inspection services. Pratik is a key leader in investments in NVI, Shenandoah, and Aeron in the GenNx360 Fund IV portfolio. Pratik led successful investments and exits in Miller Environmental and Aero3 in GenNx360 Fund III. Most recently, Pratik was responsible for the firm’s $2 billion exit from Precision Aviation Group, a global aerospace and defense maintenance and repair business in GenNx360 Fund IV. “Pratik is a disciplined and thoughtful investor with significant execution capabiliti
Vercel Brings New Agent Framework, Full-Stack Capabilities, and Enterprise Controls to Its Agentic Infrastructure Platform17.6.2026 12:13:00 CEST | Press release
As agents become the primary way software is built and deployed, Vercel connects its frontend, backend, and agent tooling into a single platform for shipping and running agents at scale. Today at Ship, its annual conference, Vercel introduced a set of new products that deepen its agentic infrastructure platform trusted by DoorDash, Helly Hansen, OpenAI, Stripe, and The Weather Company. Founder and CEO Guillermo Rauch and other Vercel leaders unveiled the lineup on stage, anchored by three shifts the products address: agents are now the dominant way software gets deployed, every application is becoming agentic, and enterprises need to run agents in production securely and at scale. The transition is well underway. Six months ago, fewer than three percent of deployments to Vercel infrastructure were triggered by coding agents. Agents now account for more than half. Token volume through Vercel's AI Gateway has grown from roughly two trillion to twenty trillion per month over the same peri
NIQ Introduces NIQ Cadence: A Compound AI Operating System for Marketing Effectiveness17.6.2026 12:00:00 CEST | Press release
One system unifies NIQ’s global data, models, and knowledge so marketers move from insight to impact faster, with deeper intelligence, at scale. NIQ (NYSE: NIQ), a global leader in consumer intelligence, today introduced NIQ Cadence, a compound AI operating system built to change how organizations measure marketing performance, optimize budgets, and act on what the data tells them. NIQ Cadence brings data and intelligence into one continuous environment, moving marketers off fragmented reports and onto a single system that empowers decision making. Marketing has never been more complex. Channels keep multiplying, data sits in silos, and the pressure to prove ROI keeps climbing. As a result, most teams still stitch insight and action together by hand, losing time and confidence at every handoff. NIQ Cadence closes that gap with one system where measurement and decision-making finally run together. “Marketing leaders don’t need more reports. They need a better rhythm,” said Jason Tate, G
Winning With AI Requires Organizational Transformation, Not Speed of Adoption, Finds New Arthur D. Little Report17.6.2026 12:00:00 CEST | Press release
To successfully embrace the power of AI, businesses need to remove organizational complexity and eliminate unnecessary work, rather than simply using it for fragmented, incremental improvements. Boards must act now to deliver this. That is the key message from AI-First or Disrupted: Beating the Nightmare Competitor, a new report from Arthur D. Little (ADL) based on concrete examples from leading organizations. Within three to five years, AI-first competitors will make faster decisions, have flatter organizations, and operate at lower costs. They will not just optimize handovers between teams, approvals, and reconciliation work; they will eliminate these complex processes entirely. AI is completely changing the economics of work and value creation, removing the need for coordination across multiple teams, while also enabling adaptive, predictive, and personalized products and services. This delivers both lower operational costs and a fundamentally stronger value proposition. However, mo
WISE Closes Oversubscribed Series D Financing Round of €30 Million, Welcoming ENEA Tech and Biomedical as Strategic New Investor17.6.2026 12:00:00 CEST | Press release
WISE S.p.A., a pioneering medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface (BCI), today announced the successful closing of an oversubscribed Series D financing round totaling €30 million. The round was joined by ENEA Tech and Biomedical, an Italian foundation dedicated to innovation and technology transfer in the biomedical sector, which enters WISE's investor base as a strategic partner. This final closing builds on the first closing of the round completed in June 2024, which included a venture debt facility from the European Investment Bank (EIB) supported by InvestEU, alongside an equity investment from new investor Wallaby S.p.A. — the family office of the Scagliarini family (GVS S.p.A.) — and existing financial partners New Frontier S.r.l., Eureka Venture SGR, and Indaco Ventures SGR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom